CDD Vault Celebrates 3-Millionth User Login with GyreOx Therapeutics
CDD is delighted to be celebrating another achievement. In December 2021, a member of UK based GyreOx Therapeutics made the lucky 3-millionth login to the CDD Vault hosted informatics platform.
Romario Ferreira-Pontes recently joined GyreOx in his first role after completing his MChem at The University of Manchester, and has joined the team in using CDD Vault for data management. He made the 3-millionth CDD Vault login during his first month at the company.
GyreOx is a privately-held biotechnology company, based on the Harwell Campus, Oxfordshire, UK and has been active since 2019. GyreOx is focused on creating novel medicines addressing complex intra-cellular targets in a wide range of diseases. Its proprietary platform technology is based on a combination of chemistry and synthetic biology deploying a set of rationally engineered enzymes. GyreOx uses its proprietary discovery platform to create unique GyrocycleTM molecules.
CDD Vault acts as an intuitive central database for GyreOx’s research data, including chemical structures and biological assay data. The ELN has become an essential tool for their project teams to ensure that all experiments are securely documented and shared within the group to ensure visibility and keep projects on track. Romario commented “CDD Vault has definitely saved me a lot of time. I think for the way that I've been using it personally, the best feature is that I can very quickly look through all of my own past entries in the ELN, as well as everyone in my team, to really easily and effectively find out what was done, when.”
Regarding the future of GyreOx, and what is to come in 2022, Founder and CEO Bill Primrose remarked, “The plans are to become a clinical stage company. The goal is to use our technology with partners. We know that pharma has lots and lots of stalled projects with particular targets, because they've got starting points, which are peptides, and they can't develop those any further. I think once we’ve validated the technology, which is what we're doing right now, then I think we'll be a partner of choice to move into this particular macrocycle modality. To give new weapons for the armamentarium against disease. We also want to take on the oncology projects that we’ve started, to develop something which we can generate clinical data for. So those are the immediate short term goals.”
CDD would like to thank Bill Primrose and the GyreOx team, it is excellent to see them making progression towards their goals while using CDD Vault to securely manage their research data. All the best for 2022!
About Collaborative Drug Discovery, Inc.
CDD’s (www.collaborativedrug.com) flagship product, “CDD Vault®”, is used to manage chemical registration, structure-activity relationships (SAR), and securely scale collaborations. CDD Vault® is a hosted database solution for secure management and sharing of biological and chemical data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy to use web interface. Available modules within CDD Vault include Activity & Registration, Visualization, Inventory, and ELN.
A complete list of more than 60 publications and patents from CDD can be found online on our resources page at https://www.collaborativedrug.com/publications-and-resources/.
Media Contact: Barry Bunin, Ph.D., Collaborative Drug Discovery, [email protected]